CHAD Therapeutics Completes Oxygen Business Sale

CHAD Therapeutics Inc. closed the $5.25 million sale of its oxygen conserving business to manufacturer Inovo Inc. “We are pleased that we have completed the sale of our oxygen conserver assets, an important step in our plan to focus our future efforts on the sleep disorder market,” CHAD President and CEO Earl Yager said. CHAD recently filed an application with the FDA for clearance to begin marketing the first of its sleep products, which Yager believes can improve the diagnosis and treatment of disorders such as obstructive sleep apnea. The company also has additional proprietary products in an advanced stage of development and a roadmap of additional product development opportunities based on its patented technology. Based in Chatsworth, CHAD Therapeutics develops, manufactures and markets respiratory care devices designed to improve the efficiency of oxygen delivery systems for home health care and hospital treatment of patients suffering from pulmonary diseases. The company is now actively pursuing the sale of its trans-filling assets.